Attacking Rare Disease IgA Nephropathy and Using a Skunkworks Approach to Get More Drugs Through the Pipeline
Renee Agular-Lucander is CEO of Calliditas Therapeutics a Sweden-based clinical-stage biopharmaceutical company.
Calliditas is focused on the rare kidney disease IgA nephropathy. While there is a genetic predisposition for this autoimmune disease, it is still not clear what triggers the condition and there is no current cure.
In this podcast Renee talks about:
Lead drug candidate Nefecon which starts at the top of the disease cascade in the ileum part of the small intestine. Delivering this disease-modifying agent directly interrupts and disrupts the beginning of the disease
How clinical trial data is showing the value of addressing the gut-renal axis and treating this indication in an organ-specific way
Other orphan indications that might benefit from this approach
What the FDA priority review of Nefecon potentially means for the 1 in every 4 adults with IgAN who will eventually succumb to kidney failure.